Esteemed Heart Surgeon Blows The Lid Off The Big Pharma

New Post Public Reply Private Reply Replies (0) Message Board
wowhappens28
281
Esteemed Heart Surgeon Blows The Lid Off The Big Pharma Statin Drug Scam

https://www.naturalblaze.com/2018/12/esteemed...-scam.html

physician’s word is often taken very seriously and with little skepticism. An opinion from one or two doctors, when made in a professional office or hospital, can persuade a worried patient to take drugs with complex side-effects, or even undergo traumatic treatments such as radiation and chemotherapy. Yet, when the same doctors, with years of experience and thousands of satisfied customers, give an opinion that questions a therapy established by mainstream medicine, the mainstream media calls them irresponsible, or quacks, or even criminals.

Many doctors are highly admirable people, but they are still human beings. They all make mistakes, they all learn from them, but the really good ones are willing to admit to them.

Which brings us to Dr. Dwight Lundell. He’s an experienced heart surgeon and retired Chief of Staff and Chief of Surgery at Banner Heart Hospital in Mesa, Arizona. Not so long ago, Dr. Lundell made the following statement of confession:

We physicians with all our training, knowledge and authority often acquire a rather large ego that tends to make it difficult to admit we are wrong. So, here it is. I freely admit to being wrong. As a heart surgeon with 25 years experience, having performed over 5,000 open-heart surgeries, today is my day to right the wrong with medical and scientific fact.

I trained for many years with other prominent physicians labeled “opinion makers.” Bombarded with scientific literature, continually attending education seminars, we opinion makers insisted heart disease resulted from the simple fact of elevated blood cholesterol. The only accepted therapy was prescribing medications to lower cholesterol and a diet that severely restricted fat intake. The latter of course we insisted would lower cholesterol and heart disease. Deviations from these recommendations were considered heresy and could quite possibly result in malpractice. It Is Not Working!

These recommendations are no longer scientifically or morally defensible.

Not surprisingly, Lundell’s statement regarding the medical establishment’s approach to treating heart disease caused a ripple in the medical industry. It challenged the validity of statins – commonly known as cholesterol-lowering medications – such as Lipitor, Crestor, Zocor, and others.

The reason Lundell’s statement created such a buzz is because statins are big business. In the United States alone, about 25% of the population takes statin medications. They cost from as little as $53 per month to more than $600. Pfizer’s Lipitor went on sale in 1997 and its lifetime sales have surpassed $125 billion. AstraZeneca’s Crestor was the top-selling statin in 2013, generating $5.2 billion in revenue that year alone. The statin industry is estimated at around $30 billion in sales per year. Nevertheless, in the United States, more die each year of heart disease than ever before.

Lundell went on to say:

The discovery a few years ago that inflammation in the artery wall is the real cause of heart disease is slowly leading to a paradigm shift in how heart disease and other chronic ailments will be treated. The long-established dietary recommendations have created epidemics of obesity and diabetes, the consequences of which dwarf any historical plague in terms of mortality, human suffering and dire economic consequences.

I have peered inside thousands upon thousands of arteries. A diseased artery looks as if someone took a brush and scrubbed repeatedly against its wall. Several times a day, every day, the foods we eat create small injuries compounding into more injuries, causing the body to respond continuously and appropriately with inflammation. While we savor the tantalizing taste of a sweet roll, our bodies respond alarmingly as if a foreign invader arrived declaring war. Foods loaded with sugars and simple carbohydrates, or processed with omega-6 oils for long shelf life have been the mainstay of the American diet for six decades. These foods have been slowly poisoning everyone.

Simply, it is the foods that are baked or soaked in soybean oil and ones that are processed for long shelf-life that are creating an extreme imbalance of omega-6 and omega-3 fats in people’s bodies. Lundell estimates the ratio of imbalance “ranges from 15:1 to as high as 30:1 in favor of omega-6.” A healthy ratio is closer to 3:1.

But what makes Lundell’s statements controversial is that cholesterol does not cause heart disease…which makes statin drugs superfluous. And he suggests a treatment to heart disease that doesn’t make Big Pharma any money:

Simply stated, without inflammation being present in the body, there is no way that cholesterol would accumulate in the wall of the blood vessel and cause heart disease and strokes. Without inflammation, cholesterol would move freely throughout the body as nature intended. It is inflammation that causes cholesterol to become trapped.

Since we now know that cholesterol is not the cause of heart disease, the concern about saturated fat is even more absurd today. The cholesterol theory led to the no-fat, low-fat recommendations that in turn created the very foods now causing an epidemic of inflammation. Mainstream medicine made a terrible mistake when it advised people to avoid saturated fat in favor of foods high in omega-6 fats. We now have an epidemic of arterial inflammation leading to heart disease and other silent killers. What you can do is choose whole foods your grandmother served and not those your mom turned to as grocery store aisles filled with manufactured foods. By eliminating inflammatory foods and adding essential nutrients from fresh unprocessed food, you will reverse years of damage in your arteries and throughout your body from consuming the typical American diet.

It probably comes as no surprise that Lundell has been portrayed as a quack by the mainstream medical establishment. The main argument to back up his “quackery” was that his medical license was revoked in 2008…although the man was already retired and had no plans to return to the surgery room. He was not called a quack when he was performing surgeries, but once he took his 25 years of practice and discerned what he believes is the cause of heart disease, it was then that he was attacked by his peers. Which brings up the question if Lundell came onto the American Medical Association’s radar as he was working on and promoting his book, The Cure for Heart Disease, which was published in 2007.

Millions of dollars are made from heart disease treatment and statin medications. This established industry does not want anyone to interfere. Lundell said it himself, “Deviations from these recommendations were considered heresy and could quite possibly result in malpractice.” And it sure is easier to discredit a retired heart surgeon and chief of surgery with 25 years of experience if you revoke his license.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 24

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
Optikos Secures CMMC Level 2, Eyeing Defense Market

Updated Category News Views 92

Optikos Levels Up with CMMC Certification In a world where cybersecurity threats are lurking around every corner, Optikos has just joined the rarefied ranks of the top 1% of U.S. defense suppliers by grabbing the CMMC Level 2 certification. Let me tell you, this isn't just some shiny badge for show; it's a gateway to big defense contracts. Crunching the Numbers Of the...

Continue Reading
BTQ Technologies Calls Investors for Key Quantum Update

Updated Category News Views 50

You know what's stirring the pot over at BTQ Technologies? A shareholder call coming up soon, and boy, it's got 'eye-opening insights' written all over it. We're talkin' Q3 financial results and, likely, a smattering of future plans on the quantum front, folks. Diving into BTQ's Quantum Vision BTQ Technologies Corp. (NASDAQ: BTQ) isn't just another tech firm banging on...

Continue Reading
Morgan County, IN: An Oasis for Balanced Living

Updated Category News Views 45

Why Morgan County? A Question for Homebuyers Ever wondered what makes Morgan County, IN, such a hot ticket for folks looking to escape the daily grind of big city life? Rachel Blacklidge, real estate wizard and hometown hero, lays it all out in a way even the most city-bound among us can appreciate. Small-Town Vibes, Big-City Access Let’s face it—sometimes the chaos...

Continue Reading
Etavopivat Aims to Tackle Sickle Cell Crisis Head-On

Updated Category News Views 140

Diving headfirst into the world of sickle cell disease, Novo Nordisk has just thrown its hat in the ring with etavopivat. Now, anyone who's been following the biotech dance knows this ain't no small feat. This investigational therapy is poised to shake things up, offering a new lifeline for those wrestling with this debilitating condition. And leaping from the Phase 3...

Continue Reading
HSBC Capital Move: Tender Offer Satisfaction Explained

Updated Category News Views 77

HSBC's Capital Reshuffle: What's Gotten Sorted? If you've been eyeballing HSBC Holdings, you know they're putting some serious skin in the game. They've just wrapped up a hefty $1.5 billion tender offer for their perpetual securities, checking off a big condition known as the New Issue Condition. Diving Into the Details of the Offer Let's break this down like you're...

Continue Reading
Longsys and Lexar Push Boundaries in Edge AI Storage

Updated Category News Views 124

Longsys and Lexar: A Revolution in Storage Ah, the tech world—it's like a fast-moving express train you just can't afford to miss. Longsys and its sidekick Lexar are in the spotlight this time, and boy, they've got some head-turning announcements. At electronica 2026 in Munich, they're playing the storage game hard. From industrial-grade mSSD to automotive solutions,...

Continue Reading
Custom Upholstered Furniture: Comfort Built to Last

Updated Category News Views 77

Rethinking Furniture Comfort: Not Just a Luxury Diving into the world of custom upholstered furniture with insights from Randy Marohn is like finding a cheat sheet for comfort. Seriously, it ain't just about plush cushions or slick fabrics—it's a bonafide science. Marohn, from Sans Furniture Inc. in good ol’ Hamburg, NY, unfolds a tale of intentional design and...

Continue Reading
AI Deception Challenges the Confidence of Fraud Defenses

Updated Category News Views 76

Fraud Week Spotlights AI Deception Alright, here's the rub: we're in Fraud Week 2026, and boy, is AI shaking the foundations of yesterday's fraud defenses! With all this AI talk, you would expect systems to be near invincible by now. But reality? A different beast altogether. AI has this knack of tripling up the complexity while pretending to solve it, making traditional...

Continue Reading
Student Letters Pour Gratitude Over Veterans Nationwide

Updated Category News Views 59

A Tsunami of Gratitude from Schools Nationwide The gesture is as vast as the nation's gratitude. To see 30,000 student letters flooding into the hands of veterans and active-duty service members is nothing short of overwhelming. This initiative by the National Heritage Academies (NHA) isn't just a token annual ritual—it's a profound statement of appreciation, showing...

Continue Reading

Top 5 Most Recently Viewed Articles

AI’s Dual Nature: Growth Potential or Path to Collapse?

Updated Category News Views 242

The Dichotomy of AI: Catalyst for Growth or Collapse? Yes, AI is a catalyst, though what it catalyzes remains uncertain. The prevailing narrative suggests that our foremost challenge is the need for affordable energy to support the burgeoning data centers of AI technology. Fortunately, solutions are emerging, including the construction of modular nuclear power plants and...

Continue Reading
Ponche Kuba Refreshes Its Look While Keeping Original Flavor

Updated Category News Views 280

Exciting New Look for Ponche Kuba Today marks an exciting chapter in the world of liqueurs as Ponche Kuba unveils its new packaging design, an evolution of its iconic Caribbean rum cream liqueur. Since its inception in 1942 by Don Jaime A. J. Sprock, Ponche Kuba has maintained a loyal following due to its unique flavor and quality. Although the aesthetic has transformed,...

Continue Reading
Unlocking Crypto Success: Double Bonuses and 100x Leverage

Updated Category News Views 129

BexBack Introduces Exciting Crypto Trading Offers BexBack is revolutionizing the cryptocurrency trading landscape with dynamic offers designed for traders looking to capitalize on recent market volatility. Following significant developments in the industry, BexBack has stepped up to provide traders with exceptional options, making it easier than ever to start trading....

Continue Reading
Innovative Partnership Between eMolecules and Optic for Drug Discovery

Updated Category News Views 75

Transforming Drug Discovery with AI Collaboration In an exciting development for the pharmaceutical industry, eMolecules, a leading chemical sourcing company, has joined forces with Optic, a digital biology firm. This collaboration aims to revolutionize the drug discovery process by leveraging the power of artificial intelligence. Together, these companies are creating a...

Continue Reading
Vivani Medical Advances Canine Health with Expanded Collaboration

Updated Category News Views 214

Collaborative Efforts to Enhance Canine Metabolic Health Vivani Medical, Inc. and Okava Pharmaceuticals, Inc. have announced an exciting expansion of their partnership, aiming to enhance the metabolic health and longevity of dogs. With a mutual vision for veterinary medicine, the collaboration focuses on the development of OKV-119, a long-acting GLP-1 therapy designated...

Continue Reading